Get startedLog in
    Picture of Pangen Biotech logo

    222110 — Pangen Biotech Cashflow Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Pangen Biotech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-8,938-4,356-3,310-4,494-4,489
    Depreciation
    Amortisation
    Non-Cash Items1,4491,2198116241,092
    Unusual Items
    Purchased R&D
    Other Non-Cash Items
    Changes in Working Capital2,173-3,103-2,349-1,228-1,642
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-3,662-4,681-3,324-3,503-3,451
    Capital Expenditures-839-772-1,474-734-485
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items1,9389,190-4,55214,963-86.1
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities1,0998,417-6,02614,229-571
    Financing Cash Flow Items-0.00477.362.759.7-23.8
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-0.00477.310,112-18,7363,175
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-2,5643,776762-8,009-847